key: cord-0268918-jj51b4e8 authors: Faulkner, E. C.; Moverley, A. A.; Hart, S. P.; Nikitenko, L. L. title: Integrated single-cell RNA sequencing analysis reveals alterations of ageing human lung endothelium heterogeneity in idiopathic pulmonary fibrosis date: 2022-03-10 journal: nan DOI: 10.1101/2022.03.08.22272025 sha: 2de8df1fbcaa3b5132cf4703ab2bbc71d295044c doc_id: 268918 cord_uid: jj51b4e8 Increasing age is the main risk factor for chronic lung diseases (CLD) including idiopathic pulmonary fibrosis (IPF). Halting or reversing progression of IPF remains an unmet clinical need due to limited knowledge of underlying mechanisms. In particular, the contribution of the endothelium to ageing in human lung under physiological conditions and in IPF remains insufficiently understood. In this study, we analysed heterogeneity of endothelium in physiologically ageing human lung and its alterations in IPF. We conducted a comprehensive in silico analysis of scRNAseq profiles of human lung tissues from older healthy donors and age-matched IPF patients (n=9 for each group) by integrating datasets from two independent cohorts. We generated a single-cell map of the ageing human lung and identified 17 subpopulations of ageing endothelium (12 for blood and 5 for lymphatic vessels, including 4 'de-differentiated'), with distinct transcriptional profiles, specific gene expression signatures and percentage contributions, revealing previously underappreciated extent of heterogeneity. In IPF lung, the balance of different endothelial sub-types was significantly altered both in terms of cell numbers and gene expression patterns, identifying disease-relevant subpopulations and transcriptional changes associated with specific signalling pathways and cellular processes. These findings reveal a previously unrecognised phenomenon of ageing human lung endothelium re-programming towards an 'IPF endothelium' state, suggesting potential avenues for therapeutic management or biomarker discovery for diagnostics or prognostics of IPF. Our study creates a conceptual framework for appreciating the heterogeneity of ageing endothelium and its alterations in CLDs and diseases associated with fibrosis in other organs, including lymphoedema and cancer. Increasing age is the main risk factor for diagnosis and prognosis of major noncommunicable diseases, including chronic lung diseases (CLDs), such as most forms of lung cancer, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) (1) . IPF is the most common, progressive and lethal interstitial lung disease with a prevalence rate of 33 to 450 per million people globally (2) . IPF progression leads to declining quality of life, respiratory failure and eventually lung transplantation or death. IPF is characterised by a histopathological pattern of usual interstitial pneumonia (UIP), comprising spatially and temporally heterogeneous deposition of collagens and other extracellular matrix (ECM) proteins within the alveolar walls, fibroblastic foci, and architectural distortion of the lung with cystic honeycomb change and fibrosis (3) . While the number of older people suffering from IPF is steadily increasing, and hallmarks of ageing, particularly cellular senescence and ECM dysregulation, are prominent in the IPF lung, the aetiology of this disease remains unclear (4) (5) (6) . Detailed understanding of cellular and molecular mechanisms underlying IPF-associated changes in ageing human lung will be essential for developing effective therapies to halt or reverse disease progression in elderly patients. Several lines of evidence implicate a role for the circulatory system, composed of blood vascular and lymphatic vessel networks, in IPF (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Some of these studies highlight structural and functional features of blood and lymphatic vessels, which are lined with a monolayer of endothelial cells (EC, or endothelium), in IPF lung, although often without a reference to or comparison between patients and age-matched controls/healthy donors (9, 14, 16) . Furthermore, the lung has two distinct blood vascular circulatory networks -(bronchial and pulmonary; (18) ) and three main networks of lymphatic vessels -in pulmonary tissue (peribronchial and perivascular -running parallel to the major airways and respiratory bronchioles, and existing in close proximity to the intralobular arterioles and small veins, or associated with alveoli) and in subpleural space (draining lymph from the surface of the organ) (19) . The precise contribution of these specialised networks and the vessel subtypes and EC subpopulations that comprise them, to the pathophysiology and progression of IPF, or other CLDs, remain insufficiently characterised, except few individual studies (20, 21) . Recent advances in single-cell RNA sequencing (scRNAseq) and big data analysis (22) have allowed characterisation of cellular heterogeneity in healthy and diseased lung, resulting in the generation of a human lung cell atlas (HLCA; (21) ) and the IPF cell atlas (23) . Several studies have also focused on dissecting phenotypic heterogeneity of human lung endothelium, using single cell transcriptional profiling, identifying six or nine subpopulations of EC in healthy and/or diseased lung (21, 24, 25) . These reports utilised data from either a diverse population of subjects (patients with IPF, COPD or other interstitial lung diseases, commonly placed together for comparison) with a range of ages (varying from 21 to 80 years in some cases), ethnicities and tobacco smoker statuses, or used samples from different areas of the lung, e.g. distal lung parenchyma (26) , longitudinal sections (24) or multiple lobes (27) . The most recent study generated cell atlases of the COPD lung for both human and murine tissues, comparative to physiologically ageing controls, identifying 6 subpopulations of EC (20). However, to date no comparison of lung endothelium has been performed between elderly IPF patients and agematched healthy individuals. As a result, currently there is a major gap in knowledge about the sub-types, properties and roles of ageing human lung endothelium in physiological conditions, IPF and other CLD including lung cancer. In this study, we have conducted the first comprehensive comparative in silico analysis of scRNAseq profiles of human lung tissues obtained from IPF patients and age-matched donors (49-72 years old for both groups) by integrating datasets from two independent cohorts, each composed of healthy and IPF lung datasets (24, 26) . We generated a single-cell map of ageing human lung, identified 17 subpopulations of ageing lung endothelium (12 and 5 for blood and 3 lymphatic vessel EC respectively) and characterised their transcriptional profiles, differences in percentage contribution and gene expression signatures. These findings reveal previously under-appreciated extent of heterogeneity of human ageing lung endothelium and its alterations (both in terms of gene expression profiles and percentage contributions of individual subpopulations of EC) in IPF patients, resulting in re-modelling towards an "IPF endothelium" state. To enable comprehensive scRNAseq data analysis of ageing human lung endothelium in IPF and to account for intra-and inter-lung heterogeneity (within and between individuals; (28)), we selected data from only those studies that contained lung tissues from both IPF patients and age-matched (49-72 years old) healthy donors. From all publicly available scRNAseq datasets of human IPF lungs (4 in total), only two, representing independent cohorts of subjects/individuals of different ethnic backgrounds, fulfilled these selection criteria and were used for generating a single dataset for integrative analysis (24, 26) . Four age-matched pairs (scRNAseq data from lung tissue samples from transplantation stage IPF patients and healthy donors) from the first database (26) matched our selection criteria and formed cohort 1 (Table 1, Figure 1A ). Five age-matched pairs from the second database (32 IPF and 28 donor samples ranging from 21 to 80 years old, (24) ), matching our selection criteria and forming cohort 2, were randomly selected for the integrated analysis in order to correspond to the number of cells analysed from cohort 1 (Table 1, Figure 1A ). In these two cohorts, the overall protocol for cell extraction and processing for scRNAseq was similar, but tissue samples were collected from different regions of the lung. Peripheral distal lung tissue (parenchyma; 1-2cm) was used in cohort 1 and longitudinal sections in cohort 2 samples. The summary of the information on cohort-specific patient characteristics and lung tissue collection sites is outlined in Table 1 , with more detailed information on sample preparation in the two datasets available in Materials and Methods. The collection from different regions across the lung presented the ideal platform to account for heterogeneity of tissue composition within and between the individual lungs included in our integrated analysis. Clustering analysis of ageing human lung tissue in each cohort identified two closely related clusters of ageing blood and lymphatic vessel EC (BEC and LEC respectively) in both (Supplementary Figure 1 A) , with their cluster identity confirmed by expression of EC-specific markers, including VWF (for BEC), prospero homeobox 1 (PROX1; for LEC) and calcitoninreceptor-like receptor (CALCRL; pan-EC) (Supplementary Figure 1 B ; (29) (30) (31) (32) ) and others (see Materials and Methods). Unsupervised sub-clustering analysis of the total ageing human lung endothelium (BEC and LEC pooled together) revealed 5 sub-populations of EC in cohort 2, closely matching COPD cell atlas data that compared ageing-matched datasets of human lung and identified 6 sub-populations of EC (20) Supplementary Figure 1 C) . In contrast, unexpectedly 12 sub-populations of ageing human lung EC were identified in cohort 1, potentially reflecting the differences in sample collection sites (Table 1 ). All EC subpopulations had distinct gene expression profiles in both cohorts (Supplementary Figure 1 Next, the integration of two datasets into one, accounting for intra-and inter-lung heterogeneity of EC in the ageing human lung and IPF-associated alterations, resulted in generation of a novel single cell map and revealing the presence of 25 distinct cell clusters (Figures 1 A and B) , based on specific gene expression patterns ( Table 1 ) that express cell type-specific markers proposed in 4 previous studies (21, (24) (25) (26) . Distinct identities of two closely related BEC and LEC clusters (11 and 20; Figure 1 B) were confirmed by focused in-depth analysis of expression of a panel of EC markers VWF, platelet endothelial cell adhesion molecule-1 (PECAM1), vascular endothelial cadherin (CDH5 or VE-cadherin) and CALCRL, and lymphatic vessel EC-specific genes (PROX1, PDPN, lymphatic vessel endothelial hyaluronan receptor 1, LYVE-1, and fmsrelated receptor tyrosine kinase 4, FLT4; Figure 1 D) (29) (30) (31) (32) . Quantitative analysis of the cell numbers for each of 25 clusters in age-matched groups revealed IPF-associated changes in ageing human lungs in both cohorts (Figure 1 E) . This reflects differences in location of tissue samples collected for scRNAseq analysis (Table 1) and matches reported in non-age matching studies contribution of different cell types to the total human lung cell population and alterations in IPF lung (20, 21, 24-26, 33, 34) Supplementary Table 2 ). Our data also uncovered changes in proportions of ageing human lung BEC and LEC populations between cohorts and conditions (Figure 1 E, Supplementary Table 3 ). Data integration revealed the comparable spatial profiles and contribution of ageing human lung EC populations in donor and fibrosis, and in individual cohorts ( Figure 1F ). Quantitative analysis demonstrated the similarity in contribution of ageing human lung EC populations in integrated dataset to two conditions (donor and IPF; Figure 1 G). In summary, the comprehensive analysis of scRNAseq profiles of human lung tissues from elderly healthy donors and age-matched IPF patients by integrating datasets from two independent cohorts enabled the generation of a novel map of individual cell populations in ageing human lung and identification of ageing human lung endothelium from blood and lymphatic vessels. This data provides a foundation for studying changes in transcriptional profiles and contribution of these cell populations, especially endothelium, within ageing human lung in IPF and other age-associated lung diseases. Next, to comprehensively decipher transcriptional signatures of ageing human lung blood vessel endothelium in IPF, we subtracted scRNAseq data for ageing human lung BEC (n=3192) from the total lung cell populations from integrated dataset (two cohorts and both conditions), and sub-clustered them ( Figure Three-dimensional pseudo-time lineage analysis of scRNAseq/transcriptional profiles of all 12 identified ageing human lung BEC sub-clusters revealed close relationships between them (Figure 2 E; Supplementary Video 1). This included a direct link between sub-cluster 5 and 5 sub-cluster 3, and manifestation of sub-cluster 0 as a "convergence point" for 7 other subclusters (1, 2, 4, 6, 9, 10 and 11) . When applied to 12 ageing human lung BEC subpopulations, the dot plot expression analysis of markers of lung EC sub-types proposed in other transcriptional studies in human and murine tissues (35) (36) (37) (38) (39) (40) identified few distinct matches (Supplementary Figure 7) . Further exploration of identities of 12 sub-populations by using these markers alongside those proposed for specific EC sub-clusters in HLCA and IPF cell atlas studies (20, 21, (23) (24) (25) , when coupled with module scoring ( suggest that our study de-convoluted ageing human lung BEC population, providing advanced resolution of its heterogeneity at a transcriptional level, increasing the number of EC sub-clusters (20, 21) and revealing previously underappreciated extend of diversity of ageing blood endothelium in human lung. Quantitative analysis of percentage contribution of cells from each sub-cluster to total BEC population in ageing human lung from healthy donors and IPF patients revealed a significant increase in representation of two sub-clusters (1 and 2) and decrease in sub-cluster 7 in IPF ( Figure 3 A-C; Supplementary Table 5 ), and their specificity by the cohort (Figure 3 D) . These findings therefore also reveal substantial alterations in cell numbers within individual subclusters of ageing human lung BEC in IPF. In summary, our study is the first to create a novel single-cell map of the ageing human lung blood vessel endothelium and identify 12 sub-clusters of BEC with distinct transcriptional profiles, individual gene and expression signatures and percentage contribution in donors and IPF patients. This knowledge provides a foundation for studying specific roles of these subpopulations of BEC within ageing human lung in IPF and could be critical to understanding pathophysiology of this and other age-associated lung diseases. The profiling of markers of EC sub-types ( (Table 1) , formed the foundation for the annotation of 12 identified ageing human lung BEC sub-clusters with novel transcriptional signatures ( Figure 4 ). The expression of the 50 sub-cluster-specific DEG ( Figure 2D ) was analysed in the total lung to determine if they were endothelial specific ( Supplementary Figure 4 A) . The majority of these DEG were modestly expressed in other cell types. To our knowledge, 39 of 50 identified sub-clusters-specific DEG have not been previously assigned as markers of individual generic subpopulations of BEC in any of the previous studies on human or mouse lung (20, 21, 24, 25, 35) . Thus, these 39 DEG novel genes were associated with ageing human lung endothelium. A pathway analysis revealed that they belong to several classes of proteins, including secreted molecules, cell surface receptors and transcription factors, and their subcellular distribution ( Supplementary Figure 4 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. Based on these findings and specific transcriptional signature derived from heatmap analysis (Figure 2 B-D), sub-cluster 0 was annotated as "de-differentiated" BEC. Sub-clusters 1 and 2 were named "bronchial venule 1 (IPF Endo 1)" and "bronchial venule 2 (IPF Endo 2)" BEC. Both clusters had distinct gene expression signatures revealed by heatmaps (Figure 2 B, D) and significant "bronchial" and "vein" identity scores ( Figure 2 F; Supplementary Figure 10 ). "Bronchial venule 1 (IPF Endo 1)" BEC sub-cluster partly, yet non-significantly, matched the "vascular endothelium (VE) peribronchial" sub-cluster signature (Figure 2 F; Supplementary Figure 6 ) which was identified by others through analysis of age-unmatched datasets of lung tissues from donors and IPF patients (24) . Both sub-clusters were annotated "IPF Endo" (1 or 2) due to the increased number of these EC sub-populations in IPF lung ( Figure 3 ). These subclusters were differentially present in the two analysed cohorts (Figure 3 A, D), thus intimately linking them to different parts of the lung (the cross-organ region and distal parenchyma in cohorts 2 and 1 respectively, Table 1 ). Sub-cluster 3 was annotated "general capillary" or "gCap" BEC due to its expression of capillary, and presence of gCap-specific markers CD36, FCN3 and IL7R (35); Supplementary Figure 7 ). Sub-cluster 4 was labelled as "intralobular arteriole" BEC due to its expression of classical arterial differentiation genes (eg. EFNB2, HEY1, GJA5; (41, 42) ; Supplementary Figure 7 , Figure 2F ). Sub-cluster 5 was labelled as "dedifferentiated capillary" BEC due to either extremely low (PECAM, vWF and CLDN5) or absent (CDH5 and CALCRL) expression levels for general EC markers (Figure 2 Figure 2F ). Sub-cluster 7 was labelled as "bronchial capillary" BEC due to its positive scoring for "bronchial" genes signature ( Figure 7 ) and S100A4, which was also associated with murine and human EC de-differentiation/Endo-MT in in vitro models ((36, 39); Supplementary Figure 7 ). Sub-clusters 10 and 11 were mainly present in cohort 1 (Figure 3 C-E), thus intimately linking their location, and hence origin, to distal parenchyma (Table 1) . Next, we used our novel signatures ( Figure 4A ) to test the hypothesis that sub-cluster 0 ("dedifferentiated" BEC, the largest one in integrated dataset; Figure 3C ) is a subpopulation of BEC, which is associated only with ageing and not non-ageing/young human lung. The comparison of an integrated scRNAseq dataset comprising transcriptional profiles of four ageing (49-66 years; donor dataset from cohorts 1; Table 1 ; (26) ) and three non-ageing/young Next, unsupervised hierarchical clustering of 12 sub-clusters of ageing human lung BEC from integrated total dataset, which was split into two separate objects (donor and IPF/fibrosis), revealed clear stratification into two groups, which we termed "capillary" (or "microvascular") and "macrovascular", as based on distinct clustering of capillary sub-clusters (3, 5, 7 and 8; Figure 4 D). In IPF, the relationships between sub-clusters were altered, with "bronchial venule 1 (IPF Endo 1)" and "intralobular venule" BEC transcriptional signature "translocating" to "capillary/ microvascular" group (Figure 4 D). In summary, the conducted comparative analysis and annotation of 12 sub-clusters of ageing human lung BEC led to identification for the first time of 4 sub-clusters of bronchial and 8 subclusters of pulmonary circulation, including 4 sub-clusters of "de-differentiated" endothelium. These findings warrant detailed analysis of the roles for these sub-clusters in ageing-associated CLDs. Differential gene expression analysis between donor and IPF for BEC subpopulations led to identification of 3596 significantly regulated (1600 down-and 1996 up-) DEG across 12 subclusters ( Figure Next, the utilisation of published gene set enrichment analysis (GSEA) libraries for the assessment of expression of marker genes, associated with ten EC-relevant cellular or biological processes, revealed significant changes in some ageing human lung BEC subpopulations in IPF ( Figure 5 D, E). This included IPF-associated alterations in EC differentiation, mesenchymal, senescence, apoptosis, proliferation, migration, angiogenesis, inflammation , vasodilation and permeability scores, reflecting sub-cluster specific pattern of response to the fibrotic lung environment in all processes, and ranging from two to 8 from total of 9 analysed sub-populations (Supplementary Figure 15 ). In summary, our study identified that the balance of EC sub-populations in ageing human lung blood vessel endothelium was significantly changed in IPF, not only in terms of cell numbers, but also DEG, revealing disease-relevant sub-clusters and alterations associated with specific signalling pathways and cellular processes. Changes in transcriptional profiles of individual sub-clusters of ageing human lung BEC related to key endothelial processes suggest implication in clinical manifestations of IPF and sub-cluster-specific functional responses in the fibrotic lung environment. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272025 doi: medRxiv preprint Finally, to comprehensively decipher the transcriptional signature of ageing human lung lymphatic vessel endothelium in IPF, we extracted scRNAseq data for LEC from the total lung from two cohorts in both conditions (689 cells) and performed unsupervised re-clustering ( Figure 1A ). This revealed two distinct cell populations of LEC consisting of five subpopulations in total (Supplementary Figure Table 9 ) datasets. Four identified LEC sub-clusters (0, 1, 2 and 4) showed high expression of LEC markers (Supplementary Figure 16 C) . Sub-clusters 0 and 2 were annotated as "intralobular lymphatic capillaries" and "subpleural lymphatic capillaries" LEC respectively, based on their high expression of PDPN, LYVE1, PROX1 and FLT4, linking to findings from studies using other methods (8, 47, 48) , and association with specific cohorts, reflecting lung tissue sample collection site (Table 1) . Sub-cluster 1 was annotated as "subpleural lymphatic collectors" LEC, as based on their low expression of LYVE1 and PROX1 (8, 48) . Sub-cluster 4 was identified as "intralobular quiescent para-vascular lymphatics" LEC, as based on high levels of PDPN and low levels of LYVE1 and PROX1 expression observed for this sub-type of lymphatic vessels (49) . (49), suggest that it is formed by "proliferating para-vascular lymphatics" LEC. Interestingly, two sub-clusters (1 and 2) originated from cohort 1 and another three (0, 3 and 4) from cohort 2 (Supplementary Figure 19 C-E, Supplementary Table 9 ). Therefore, annotations matched sample collection locations, with subpleural LEC sub-populations restricted to distal lung samples (Table 1) . Finally, the utilisation of GSEA libraries for the assessment of expression of marker genes associated with ten selected processes relevant to EC biology in LEC subpopulations revealed significant alterations in ageing human lung in IPF (Supplementary Figure 20) . These changes indicate sub-cluster specific pattern of response to the fibrotic lung environment in all processes, ranging from zero to three from total of five analysed sub-populations. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. ; In summary, our study is the first to identify five sub-clusters of LEC in ageing human lung. Heterogeneity of LECs was altered in terms of transcriptional profiles and DEG for individual LEC sub-clusters, but without significant alterations in cell numbers. These changes were associated with key endothelial processes, suggesting implication in clinical manifestations of IPF and warranting further investigations for understanding their roles in the fibrotic lung environment and age-associated CLDs. Ageing is the key risk factor for IPF, although the aetiology of this disease and means of slowing or reversing its progression, remain unclear due to limited understanding of the underlying cellular and molecular mechanisms. Previous studies, aimed at characterising human lung cell heterogeneity and generating cellular atlases, have been predominantly conducted using diverse datasets from healthy donors and patients with different diseases covering a wide range of ages, ethnicities and other characteristics (21, 24-26, 33, 34) . This complicated the deconvolution of a highly heterogeneous population of specialised cells in human lung, including changes associated with the ageing process itself or further impacts/exacerbations caused by specific age-associated diseases. For this study, we selected only ageing human lung tissue scRNAseq profiles from two cohorts (24, 26) for integrative analysis, overcoming these limitations and generating a novel map of individual cell populations in age-matched healthy donors and IPF patients. Unsupervised clustering revealed the presence of 25 distinct cell populations, based on specific gene expression patterns (Figure 1 Table 1 ). Previous studies attempting to characterise changes in transcriptome of the ageing compared to young human lung used bulk RNAseq data, with no comparison to samples from lung diseases in one and inferring cellular composition of the ageing lung in healthy donors and in coronavirus disease-2019 (COVID-19) patients in another (50, 51) . A more recent study used human and murine tissues to generate a cell atlas of physiologically ageing and agematched COPD lungs (20). To our knowledge, the comparative scRNAseq analysis of human lung tissue of elderly IPF patients against age-matched healthy donors has not been conducted. Therefore, the generated in our study integrated multi cohort scRNAseq map of individual cell populations, including endothelium, in age-matched human lung provides a foundation for studying their transcriptional profiles and contribution within respective lung tissue regions and microenvironments in IPF and other age-associated lung diseases. Our identification of 17 sub-clusters of EC (12 BEC and 5 LEC) in the ageing human lung with distinct molecular signatures reveals previously underappreciated extent of heterogeneity of ageing human lung endothelium. Herein, we identify 12 sub-clusters of BEC in ageing human lung, with separation of four sub-clusters of bronchial circulation from eight sub-clusters of pulmonary circulation. Previous scRNAseq studies suggested five general and eight specific subpopulations of BEC in human and/or mouse lung (20, 21) . Several scRNAseq studies investigated heterogeneity of EC in murine lung tissues, yet to our knowledge only one focused on ageing animals, identifying between five and eight sub-populations (20, 35, 52, 53) . Furthermore, our study identifies 5 sub-clusters of ageing human lung LEC using scRNAseq analysis, matching LEC subpopulations characterised by immunohistochemistry in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272025 doi: medRxiv preprint 10 human lung (8, 47) . To our knowledge, the present study is the first description of distinct molecular signatures of LEC sub-clusters, revealing the heterogeneity of ageing human lung lymphatic endothelium. No studies analysed the transcriptional profile of lymphatic vessel endothelium at a single cell level in the mouse or human lung (from either ageing or young patients), or any other organs, except lymph nodes (54) (55) (56) . Previously unrecognised heterogeneity of ageing human LEC warrants further study to decipher their role in lung tissue. DEG signatures for 17 subpopulations of ageing human lung endothelium contain 59 novel candidate genes (39 for BEC and 20 for LEC) for further investigation of their specific roles. A pathway analysis of the DEG (Supplementary Figure 4 B -D) provides a platform for future studies of their, especially cell surface receptors and genes linked to cell metabolism, subcluster specific roles in ageing human lung in health and pathophysiology of CLDs. Our study identified for the first time the presence of 4 sub-clusters of "de-differentiated" BEC in lungs from ageing human lung (49-72 years old) and their absence in young (21-29 years old) donors. Findings from our scRNAseq analysis in IPF, including expression of transcripts encoding surfactant proteins in some sub-populations, are in accordance with histological and molecular reports about the plasticity of endothelium and loss of EC identity, frequently associated with Endo-MT, in vascular disorders (57) (58) (59) (60) (61) . In our study, decreases in EC differentiation scores in three BEC sub-clusters (0, 4, 7) and one LEC sub-cluster (0) in IPF co-occurred with increases in mesenchymal score. These findings suggest that Endo-MT is one of the features of the ageing endothelium in IPF, but only in selected BEC and LEC subclusters. Lower average number of genes per cell underlying ageing human lung BEC dedifferentiation in sub-clusters zero and five has been also observed in few sub-populations of other cell types within ageing human lung in our study, concordant to findings for individual cell sub-populations identified in scRNAseq studies of ageing tissues from other organs (62, 63) . Therefore, this does not appear to be a BEC-specific feature. Sub-clusters zero and five were also negative for other cell type specific markers from the total lung, indicating they are EC and not another cell type. The age-associated de-differentiation of the significant proportion of human lung endothelium sub-populations is the most likely explanation for their "contribution" to sub-cluster zero, which contained nearly 30% of cells within an integrated scRNAseq dataset and manifested as a convergence point for 7 sub-clusters of BEC in ageing human lung tissues samples. The observed down-regulation of EC markers in the ageing human lung could serve as an explanation for immunohistochemistry-based (using CD31, vWF or CD34) reports suggesting a loss of vasculature associated with fibrosis development (9, 64) . Cell cycle analysis revealed that the majority (over 50%) of the cells in sub-clusters zero, four-to-seven and nine in ageing human lung were in S phase. Cell cycle arrest and the increase in S phase proportion have been linked to cell senescence in studies using in vivo or in vitro models, including murine lung EC (63, 65) . All nine analysed ageing human lung BEC subpopulations had positive senescence scores, which increased only in two sub-populations in IPF. Senescence has been classified as a hallmark of ageing in humans and mice (4), but remains challenging to analyse in human tissues and EC within any organ. The presence of senescent endothelium has been associated with hypertension and increased cardiovascular disease risk in elderly patients (66) (67) (68) . To our knowledge, the cellular senescence in ageing human lung endothelium has not been appreciated at a single cell level before. Therefore, its contribution to alterations in vessel function in lungs of older people under physiological conditions and in CLDs merits further investigation. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint De-differentiation (due to Endo MT, global reduction in gene expression and/or partial senescence) of highly specialised EC sub-clusters in ageing human lung is likely to contribute to alterations of function of individual vessel sub-types comprising respective circulatory blood vascular and lymphatic systems. More detailed studies are warranted using tissue samples and in vitro models utilising primary lung EC (blood and lymphatic) in order to advance our understanding of the contribution of endothelium de-differentiation in ageing human lung to the pathogenesis and pathophysiology of IPF and other age-associated CLDs. Our study revealed substantial alterations in heterogeneity of ageing human lung endothelium in IPF patients, involving changes in the percentage contribution and transcriptional profiles of individual sub-populations of EC. scRNAseq analysis of ageing human lung showed a significant increase in cell numbers in two ("IPF Endo 1" and "IPF Endo 2") and a decrease in one ("bronchial capillary") BEC sub-populations, and no significant changes in cell numbers in LEC sub-populations in IPF. These novel findings are in accordance with IPF-associated changes in cell numbers for 'VE peribronchial' sub-cluster, which was identified by conducting age-unmatching analysis of lung tissue samples (24) . This sub-cluster shares a degree of similarity with two sub-populations of ageing human lung BEC identified in our age-matching study (IPF Endo 1 and 2), that are transcriptionally distinct and derived from two independent cohorts (Figure 2 F) , with only one being from the same scRNAseq dataset as 'VE peribronchial' sub-cluster. Changes in transcriptional profiles of individual sub-clusters of ageing human lung EC related to key endothelial processes suggest an implication in IPF pathophysiology and subcluster-specific functional responses in the fibrotic lung environment. Alterations in three BEC sub-clusters from IPF lung included mapping to IPF canonical signalling pathways. This finding suggests a previously unrecognised direct involvement of 'de-differentiated', 'aerocyte' and 'de-differentiated arteriole' BEC from ageing human lung in IPF. Moreover, the association of DEG in other EC sub-clusters from IPF lung with fibrotic signalling (hepatic fibrosis etc.) or inflammatory pathways imply their roles in IPF lung microenvironment. The "IPF Endo 1" sub-cluster translocation from the macrovascular to the capillary/microvascular group in IPF suggests a shift in the transcriptional phenotype of this sub-cluster to a capillary/microvascular-like endothelium, with implied changes to its permeability. Previous studies of lung vasculature in IPF suggest a contribution of blood vessel dysfunction (16) , aberrant angiogenesis (69) and increased permeability of blood vessels to fibrotic lung microenvironment and disease progression (14, 15) . Two of the most common comorbidities in IPF are hypertension and vascular disorders (70, 71) , suggesting that there may be systemic as well as lung endothelial dysfunction. Our data suggest that eight BEC subclusters show decreases in vasodilation score in IPF compared to the ageing lung with four of these sub-clusters also showing decreases in permeability score in the fibrotic lung. To our knowledge, no functional studies of lymphatic systems and vessel sub-types or LEC composing them performance in ageing human lung or IPF lung have been conducted to date. This warrants further research dissecting the function of the ageing human lung endothelium in IPF, with implications for advancing an understanding of specific roles that individual blood and lymphatic EC subpopulations play in pathophysiology and progression of this disease. Therapy for IPF patients aims to slow disease progression and maintain lung function (72, 73) . The small molecule tyrosine kinase inhibitor drug nintedanib, one of two approved disease-modifying therapies for IPF, acted on in vitro cultured human pulmonary microvascular EC to decrease TGF-β2-, TNF-α-and IL-1 β-induced Endo-MT (74) . The role of ageing human lung endothelium in the pathogenesis and progression of IPF remains is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272025 doi: medRxiv preprint understudied, partly due to a lack of experimental models which mimic the natural risk factors for this age-associated disease. Understanding of the properties of IPF endothelium and its functions within pre-fibrotic areas and fibrotic lung microenvironment could present new avenues for management of this debilitating and life-threatening disease. In summary, our study discovered the phenomenon of the distinct "IPF endothelium" phenotype/state, which is based on findings of altered heterogeneity of human ageing lung endothelium from blood and lymphatic vessels in IPF, which contributes to a UIP pattern. We propose that the maintenance of EC heterogeneity, including properties and functions of individual BEC sub-types, in ageing human lung has the potential to improve patients' quality of life, prognosis and protect lung function in IPF. Our molecular findings should help with building a conceptual framework for appreciating the endothelium as a significant contributor within the tissue microenvironments in ageing human lung and a probable target for diagnostics, prognostics and therapy in IPF, other CLDs and diseases associated with fibrosis in other organs, including lymphoedema and cancer. This work was supported by Kate Garthwaite Pulmonary Fibrosis Research Fund, the Endothelial Cell Research Fund and University of Hull PhD Scholarships Fund for "Health Global Data Pipeline (Health*GDP) for biomedical research and clinical applications." cluster. None. For integrative analysis, lung tissue samples were selected only from age-matched (49-72 years old) donors and IPF patients, and only from those studies that contained samples (cohorts) for both conditions. From all publicly available data sets investigating scRNAseq in IPF and donor lungs (4 in total), only two data sets met this selection criteria representing independent cohorts of subjects/individuals of different ethnic backgrounds. IPF samples and age-matched donor samples in cohort 1 were selected from the gene expression omnibus (GEO) GSE122960_RAW (26) and in cohort 2 -from GSE136831_RAW (24) . Only 4 age-matched pairs (scRNAseq data from lung tissue samples from 4 transplantation stage IPF patients and 4 healthy donors) from the cohort 1 (26) matched our selection criteria. Only 5 age-matched pairs from the cohort 2, consisting of 32 IPF and 28 donor samples, ranging from 21 to 80 years old and matching selection criteria (24) were randomly selected for the integrated analysis. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272025 doi: medRxiv preprint 13 More samples were selected in cohort 2 as they contained less cells per sample than cohort 1. The number of cells analysed per cohort was matched as close as possible. The samples were prepared using overall very similar protocols, but with three differences. Firstly, the samples were collected from peripheral distal lung tissue (parenchyma; 1-2cm) in cohort 1 and from longitudinal sections from apical to basal segments of the lungs in cohort 2. Secondly, cohort 2 samples were processed to derive single cells and then frozen in liquid nitrogen until processed in batches. Samples in cohort 1 were processed as soon as single cells were obtained from tissues. Thirdly, there were variations in reagents for the sample collection processes. The summary of the information on cohort-specific patient characteristics and lung tissue collection sites are outlined in Table 1 . For the analysis of young vs old lung, three samples of young lung (aged 21-29; GSE122960_RAW; (26) ) and the healthy elderly donor samples from cohorts 1 and 2 (n=9, aged 49-66, Table 1 ; GSE122960_RAW, (26); GSE136831_RAW, (24)) were used. The individual samples were given the value 'age' and were labelled as 'young' and 'old' respectively. Seurat version 4 (v4) was used to perform dimensionality reduction, clustering, and visualization for the scRNAseq data (75) . Each individual selected sample was loaded from GEO, and the percentage of mitochondrial genes were calculated for each cell. Cells containing >5000, <200 identified genes or >20% of mitochondrial genes were removed. SCTransform with default parameters was used to normalize and scale the data, and dimensionality reduction was performed using PCA on the top 2000 most variable genes. Each individual sample was processed, and endothelial cells were identified before being saved as an R object before merging all samples into a total Seurat object, performing integration and clustering, as indicated below. Unique molecular identifiers (UMI) for the remaining after filtering cell barcodes were analysed using the Seurat v4. The UMI counts were normalised using a scale factor of 10,000 UMIs per cell and then natural log transformed using a pseudo count of 1. Integration, embedding and clustering were performed as recommended by Seurat v4 (22) . Briefly, the top variable genes within each dataset were selected using the FindVariableFeatures function using the "vst" parameter. Shared patterns of variance in these genes within each dataset where then used to integrate the datasets using Seurat's FindIntegrationAnchors and IntegrateData, then the resulting integrated expression matrix was scaled using Seurat's ScaleData function. Scaled values from the integrated assay were subject to principal component analysis (PCA). Principal components (PCs) were then subject to feature selection based on ranked contribution to variance. Selected PCs were used to estimate Euclidean distances between cells in featurespace, and cells are graph embedded with edges connecting the nearest neighbours for each cell using the FindNeighbors function. This network of connected cells was then subject to Louvain clustering. The range of possible resolutions to identify these sub-clusters was visualised using clustree R package. Resolution 0.5 was utilised for this analysis and throughput the study. This is comparable to widely used 0.6-0.8 range, which enables avoiding over-clustering (76) . For visualization, cell distances and their graph embeddings were subject to uniform manifold approximation and projection (UMAP), where cells are plotted in two- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272025 doi: medRxiv preprint 14 dimensional feature-space, such that cells with similar transcriptional profiles will appear closer to one another. Further classification of the clusters was preformed using the FindAllMarkers function to identify differentially expressed genes (DEG) between clusters. These DEG were then additionally screened using Violin plots for the expression of these DEG across all clusters. Following clustering and visualisation of the human aging lung clusters using UMAP, we categorized cell types based on expression profile of classical lineage markers reported by others in the IPF cell atlas covering lung from various ages (21-80) (23) . Endothelial cell (EC) cluster was identified using classical (platelet endothelial cell adhesion molecule-1, PECAM1; vascular endothelial cadherin, CDH5; claudin 5, CLDN5) and novel (calcitonin-receptor-like receptor, CLR, encoded by CALCRL gene) pan-endothelial markers (29) (30) (31) (32) 43) . These were further classified into two sub-sets -blood vessel ECs (BEC; based on von Willebrand Factor, vWF, expression) and lymphatic vessel ECs (LEC; based on expression of prospero homeobox 1, PROX1; podoplanin, PDPN; lymphatic vessel endothelial hyaluronan receptor 1, LYVE1 and fms related receptor tyrosine kinase 4, FLT4). Two subsets consisting of only BEC or LEC were created and used for downstream analyses of physiologically aging lungs and IPF lungs from elderly patients. Essential quality controls (filtering data, normalization and endothelial identification; (62)) were conducted for the datasets from individual cohorts ( Figure 1A) to confirm comparable quality (uniform reads and presence of clusters of lung cell types in integrated dataset; Supplementary Figure 1 ; Figure 1B) The data was screened to assess the presence of clusters and sub-clusters containing a low number of genes per cell (62) . The number of genes per cell for each cluster in the total lung data was plotted in a violin plot. All of the 25 identified in total ageing human lung clusters were sub-set into their own SeuratObject and were re-clustered to identify sub-clusters. All sub-clusters of the ageing lung were analysed for the number of genes per cell for each cluster. This information was used to confirm if the low number of genes per cell was cell type specific. The expression of a panel of endothelial progenitor markers (CD34, PTPRC, KIT, POU5F1, MYC, PROM1, CXCR4, TEK, GYPA, NT5E and SPN; (77) ) in BEC sub-clusters was also analysed using violin plots. We performed a pseudo-time-based cell trajectory analysis using the R package Slingshot (78) . The slingshot wrapper function was performed with the UMAP dimensionality reduction and cluster labels as in Seurat objects to identify the trajectory. The subclustered ECs were prepared for processing using the slingshot function as SingleCellExperiment function. The slingshot trajectories are calculated such that each trajectory has a single start and end point. For clarity and brevity, multiple trajectories were plotted on the same graph. The Seurat object for the sub-set BEC and LEC were split using the Seurat SplitObject function by sample condition (donor and fibrosis). The objects were then quired using publicly available transcriptional signatures (GOBP cellular senescence (senescence), Hallmark apoptosis (apoptosis), GOBP endothelial cell proliferation (proliferation), GOBP blood vessel is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272025 doi: medRxiv preprint endothelial cell migration (migration), angiogenesis (angiogenesis), GOBP inflammation (inflammation), GOBP vasodilation (vasodilation) and GOBP regulation of vascular permeability (permeability)) from the GSEA website ((79); http://www.broad.mit.edu/gsea/) developed by the BROAD institute. The libraries for EC differentiation, LEC differentiation and Endo MT were developed from literature. GSEA results should be interpreted as alterations to these processes, not simple increases or decreases as the values may suggest. Therefore, a change in expression of genes outlined in GSEA libraries is termed as a process "score" (s), e.g., EC differentiation or Endo-MT scores etc. The 'scoring' was calculated based on the difference between the average expression levels of the gene set in a particular sub-cluster compared to the total population of cells. "Positive" or "negative" score would suggest that this group (module) of genes is expressed in a particular cell at a higher or lower level respectively, than expected, given the average expression across the cell population. Individual cells were scored using the Seurat function AddModualScore. These scores were then visualised using the Seurat RidgePlot function. A full list of the genes used are summarised in Supplementary Table 8 . The Seurat object for the sub-set BEC and LEC were further sub-set so that each cluster became a separate Seurat Object. The active identity of each cluster was then set to sample condition (donor or IPF groups). The Seurat function FindMarkers function was used to identify the differentially expressed genes (DEG) between donor and IPF groups. These genes were then exported into an .xlxs file, along with p-values, logFC and adjusted p-values. This was performed for every sub-cluster. The lists of DEG were uploaded separately into Qiagen IPA software (QIAGEN Inc., https://digitalinsights.qiagen.com/IPA). A core expression analysis was run for each list, taking into account only genes with Wilcoxon rank sum test P < 0.05 and querying only human processes. The pathways which had a definitive z score were then summarised in Figure 5 C. IPA's z-score indicates a predicted activation or inhibition of a pathway/gene, where a negative z value connotates an overall pathway's inhibition, and a positive z value connotates an overall pathway's activation. Analysis of cell type specific marker genes was performed using the FindAllMarkers function in Seurat v4. This utilises the Wilcoxon rank sum test, with p values adjusted for multiple comparisons using the Bonferroni method. Adjusted p-values of <0.05 were considered significant. Significance cell cycle analysis between sample condition was tested using a chi-square test. P < 0.05 was considered significant. Analysis of the cell scoring assay was performed using a Shapiro Wilcoxon test to test for normality and Mann-Whitney U test. P < 0.05 was considered significant. Table 1 ; (24, 26) ) were subjected to quality control and merging into an integrated Seurat V4 object for subsequent analysis. Endothelial cell (EC) clusters were identified using pan-endothelial and lymphatic-specific markers. 3192 blood vessel endothelial cells (BEC) and 659 lymphatic vessel endothelial cells (LEC) were identified, and sub-clustered for their characterisation and comparison in donor and IPF is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Table summarising the information taken into account for naming/annotating sub-clusters, including gene signatures, sample location by cohort, circulation tree and cell numbers (by condition -donor or IPF/fibrosis). A Key colour code for sub-clusters is the same as in Figures 2 and 3 . B Sample location (by cohort) information corresponds to Table 1 . DLP = distal lung parenchyma, LABS = Longitudinal apical to basal segments. C Cell number dot plots corresponds to data in Figure 3. (B) An example of a histogram (ridgeplot) for the signature 1 in all sub-clusters in both conditions (donor and IPF/fibrosis). Colours are the same as in the A Key. (C) Table of average module scores of signatures (S1-S11) across all clusters. Signatures 0 and 5 could not be constructed due to a lack of differentially expressed genes (See Figure 2D ). See Materials and Methods for full information. Coral red intensity represents sub-clusters with a positive module score for signatures. (D) Dendrogram (cluster tree) and dot plot of sub-clusters split by condition (donor on the left and fibrosis on the right). were excluded from analysis, as they contained too few cells to analyse between conditions. (C) Bar chart detailing the results of the IPA of statistically significant altered pathways. Blue colour represents a negative Z score (down) and orange represents a positive Z score (up). DEG from three sub-clusters (4, 6 and 7) did not significantly associate with any pathways and from two others (9 and 10) had too few cells in the IPF group for analysis. Ingenuity pathway analysis (IPA) was performed as described in Materials and Methods. (D, E) Published gene set enrichment analysis (GSEA) libraries were utilised for the assessment of expression of marker genes associated with ten selected key/relevant to EC biology processes. Samples were assigned module scores using the Seurat function AddModualScores based on genes used on GSEA website. Please see Materials and Methods section for further details, including scoring and interpretation. Full gene lists are available in Supplementary Table 8 . Key colour code for sub-clusters is the same as in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272025 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272025 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272025 doi: medRxiv preprint Risk factors for the development of idiopathic pulmonary fibrosis: A review Global incidence and prevalence of idiopathic pulmonary fibrosis Overview of idiopathic pulmonary fibrosis, evidence-based guidelines, and recent developments in the treatment landscape The hallmarks of aging Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK Pathogenesis of idiopathic pulmonary fibrosis Lymphatic System in Cardiovascular Medicine The disappearance of subpleural and interlobular lymphatics in idiopathic pulmonary fibrosis. Lymphatic research and biology Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. American journal of respiratory and critical care medicine Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms Lymphangiogenesis as a Prerequisite in the Pathogenesis of Lung Fibrosis. in vivo Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis Increased lymphatic vessel length is associated with the fibroblast reticulum and disease severity in usual interstitial pneumonia and nonspecific interstitial pneumonia Gadofosveset-enhanced lung magnetic resonance imaging to detect ongoing vascular leak in pulmonary fibrosis Dynamic contrast-enhanced magnetic resonance imaging of the lung reveals important pathobiology in idiopathic pulmonary fibrosis Vascular permeability in the fibrotic lung Idiopathic pulmonary fibrosis: pathogenesis and management Introduction to the anatomy and physiology of pulmonary circulation Lymphatic Changes in Respiratory Diseases: More than Just Remodeling of the Lung? Characterization of the COPD alveolar niche using single-cell RNA sequencing A molecular cell atlas of the human lung from single-cell RNA sequencing Integrative single-cell analysis The idiopathic pulmonary fibrosis cell atlas Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis Integrated single-cell atlas of endothelial cells of the human lung Single-cell transcriptomic analysis of human lung provides insights into the pathobiology of pulmonary fibrosis. American journal of respiratory and critical care medicine Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity Expression of the endothelial markers PECAM-1, vWf, and CD34 in vivo and in vitro Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype Singlecell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis A cellular census of human lungs identifies novel cell states in health and in asthma Capillary celltype specialization in the alveolus Extracellular S100A4 affects endothelial cell integrity and stimulates transmigration of A375 melanoma cells HES and HERP families: multiple effectors of the Notch signaling pathway Protein network analyses of pulmonary endothelial cells in chronic thromboembolic pulmonary hypertension Silencing of S100A4, a metastasis-associated protein, in endothelial cells inhibits tumor angiogenesis and growth A molecular atlas of cell types and zonation in the brain vasculature Molecular control of arterial-venous blood vessel identity Arterial-venous specification during development Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues Evolving functions of endothelial cells in inflammation Causal analysis approaches in ingenuity pathway analysis Angiopoietins: a link between angiogenesis and inflammation Intralobular pulmonary lymphatic distribution in normal human lung using D2-40 antipodoplanin immunostaining Increased number and altered phenotype of lymphatic vessels in peripheral lung compartments of patients with COPD Lymphatic Proliferation Ameliorates Pulmonary Fibrosis after Lung Injury The aging transcriptome and cellular landscape of the human lung in relation to SARS-CoV-2 Molecular programs of fibrotic change in aging human lung Defining the role of pulmonary endothelial cell heterogeneity in the response to acute lung injury Single-cell transcriptional heterogeneity of lymphatic endothelial cells in normal and inflamed murine lymph nodes Single-Cell Survey of Human Lymphatics Unveils Marked Endothelial Cell Heterogeneity and Mechanisms of Homing for Neutrophils A Single-Cell Transcriptional Roadmap of the Mouse and Human Lymph Node Lymphatic Vasculature Pulmonary surfactant protein a is expressed in mouse retina by Müller cells and impacts neovascularization in oxygen-induced retinopathy The Dual Role of Surfactant Protein-D in The molecular basis of endothelial cell plasticity Endothelial to mesenchymal transition (EndMT) and vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis Single-cell analysis of olfactory neurogenesis and differentiation in adult humans Mechanisms of cellular senescence: cell cycle arrest and senescence associated secretory phenotype Vascular remodelling in the pathogenesis of idiopathic pulmonary fibrosis The role of senescent cells in ageing Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction Aging and vascular endothelial function in humans The ageing endothelium, cardiovascular risk and disease in man Idiopathic pulmonary fibrosis (IPF): an overview Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation Integrated analysis of multimodal single-cell data. bioRxiv Current best practices in single-cell RNA-seq analysis: a tutorial Endothelial progenitor cells: mobilization, differentiation, and homing Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles We thank all donors who participated in the several studies analysed in this manuscript and the authors who made these rich datasets publicly available. We acknowledge Chris Collins leading support team of the Viper High Performance Computing facility of the University of Hull for their assistance. We thank; Professor Adrian Harris, Professor Tatsuo Shimosawa, Dr. Sarah De Val, Dr. Stephen Henderson, Dr Markus Queisser, Dr. Veronica Carroll, Mr Matthew Morfitt and Mrs Shirin Hasan for their constructive feedback on this manuscript. We specially thank Dr Camille Ettelaie for their contribution towards supporting this research.